{"id":186,"date":"2026-08-19T09:20:51","date_gmt":"2026-08-19T07:20:51","guid":{"rendered":"https:\/\/micromedicalsolutions.net\/about-us\/"},"modified":"2026-10-31T06:03:36","modified_gmt":"2026-10-31T05:03:36","slug":"about-us","status":"publish","type":"page","link":"https:\/\/micromedicalsolutions.net\/int\/about-us\/","title":{"rendered":"About Us"},"content":{"rendered":"
\n\n\t\n\t\n\t\n\t
\n\t\t
\n\t\t\t\n\t\t<\/div>\n\t<\/div>\n<\/section>\n\n\n
\n\n\t\n\t\n\t\n\t
\n\t\t
\n\t\t\t\n\n

Our Mission<\/p>\n\n\n

A disease that is common, growing, and treatable if it\u2019s diagnosed in time<\/h2>\n\n\n

We are committed to reducing the number of preventable amputations worldwide, thereby reducing the significant morbidity, mortality, and burden of Critical Limb-Threatening Ischemia (CLTI) disease in people living with Peripheral Arterial Disease (PAD).<\/p>\n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\n\n\n

\n\n\t\n\t\n\t\n\t
\n\t\t
\n\t\t\t\n\n

The Scale of the Problem<\/p>\n\n\n

A very complicated and highly devastating disease<\/h2>\n\n\n

Despite falling rates in some regions, prevalence of PAD is climbing as the global population ages and grows. Amputation remains, far too often, the default treatment option.<\/p>\n\n

\n\t
\n\t\t
\n\t\t\t\n
\n\t\t\t360 million<\/span>\n\t\t\t\tProjected global PAD cases by 2050, a 220% rise from today, with estimates ranging 270\u2013450 million1<\/a><\/sup><\/span>\n\t\t<\/div>\n\n
\n\t\t\t236 million<\/span>\n\t\t\t\tPeople currently affected worldwide under the broader lower-extremity PAD (LEPAD) definition2<\/a><\/sup><\/span>\n\t\t<\/div>\n\n
\n\t\t\t11\u201323 million<\/span>\n\t\t\t\tPeople living with CLTI globally3<\/a>,4<\/a>,5<\/a>,6<\/a><\/sup>, an estimated 5\u201310% of all PAD patients.<\/span>\n\t\t<\/div>\n\n
\n\t\t\t50\u201365%<\/span>\n\t\t\t\tCLTI patients have a type of diabetes.22<\/a><\/sup><\/span>\n\t\t<\/div>\n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\n\n\n
\n\n\t\n\t\n\t\n\t
\n\t\t
\n\t\t\t\n
\n\t\n
\n\t\n\n
\"\"<\/figure>\n\n\n<\/div>\n\n
\n\t\n\n

Diabetes<\/h3>\n\n\n

An estimated 589 million adults aged 20\u201379 are living with diabetes, representing 11.1% of the world\u2019s population in that age group. The number is projected to rise to 853 million (about 13% of adults) by 2050.8<\/a><\/sup><\/p>\n\n\n

Amputation<\/h3>\n\n\n

10\u201320% of patients with CLTI ultimately require a major amputation, despite advances in limb salvage. This corresponds to an estimated 2\u20135 million people worldwide living with or eventually undergoing major limb amputation related to CLTI.5<\/a><\/sup><\/p>\n\n\n

Diabetes is present in approximately 50\u201365% of CLTI patients,22<\/a><\/sup> so diabetes-related amputation statistics are often used as a surrogate. A recent global meta-analysis estimated annual diabetes-related incidence of major amputations at 94.8 per 100,000 people with diabetes, and minor amputations at 140.0 per 100,000 people with diabetes.7<\/a><\/sup><\/p>\n\n\n

Population-based studies report overall major lower-extremity amputation rates ranging from 3.6 to 68.4 per 100,000 persons annually, while approximately 22% of untreated CLTI patients undergo major amputation within one year. Major amputation rates are declining in many high-income countries but continue to rise in many low- and middle-income countries.5<\/a><\/sup><\/p>\n\n\n

Without timely revascularization, limb amputation occurs in approximately 25%\u201330% of CLTI patients within one year of diagnosis.9<\/a>,10<\/a><\/sup><\/p>\n\n\n

Percutaneous transluminal angioplasty and stenting represented 78% of all U.S. critical limb ischemia interventions in 2025, up from 62% five years earlier, due to shorter recovery times and lower hospital costs.5<\/a><\/sup><\/p>\n\n\n<\/div>\n\n\n<\/div>\n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\n\n\n

\n\n\t\n\t\n\t\n\t
\n\t\t
\n\t\t\t\n\n

Amputation<\/p>\n\n\n

An Unacceptable First Option<\/h2>\n\n
\n\t\n
\n\t\n\n

In the United States<\/h3>\n\n\n

– The best estimate for the prevalence of PAD in the US in 2020 is 19 to 21 million and continues to be underestimated.11<\/a><\/sup><\/p>\n\n\n

– Nearly 2 million people are living with limb loss.12<\/a><\/sup><\/p>\n\n\n

– Among those living with limb loss, the main causes are vascular disease (54%), including diabetes and peripheral arterial disease, trauma (45%) and cancer (less than 2%).12<\/a><\/sup><\/p>\n\n\n

– Approximately 185,000 amputations occur every year.13<\/a><\/sup><\/p>\n\n\n

– In 2020, the direct medical costs of major amputation were $13.4 billion.14<\/a><\/sup> The majority of these costs are inpatient, because the Centers for Medicare & Medicaid Services pay almost 80% of the amputation bill.15<\/a><\/sup><\/p>\n\n\n

– African-American patients are up to four times more likely to undergo an amputation than white patients.16<\/a><\/sup><\/p>\n\n\n

– Nearly half of people who lose a limb to vascular disease die within five years, a higher rate than for breast, colon, or prostate cancer.17<\/a><\/sup><\/p>\n\n\n

– Up to 55% of people with diabetes who lose one leg will lose the second within 2\u20133 years.18<\/a><\/sup><\/p>\n\n\n

– An angiogram reduces the odds of undergoing amputation by 90%.19<\/a><\/sup> Despite this, 54% to 67% of CLI patients have no angiogram performed prior to major amputation.20<\/a>,21<\/a><\/sup> Consequently, requiring an angiogram prior to major amputation and denying reimbursement if one is not performed should significantly reduce amputations.<\/p>\n\n\n<\/div>\n\n

\n\t\n\n
\"\"<\/figure>\n\n\n<\/div>\n\n\n<\/div>\n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\n\n\n
\n\n\t\n\t\n\t\n\t
\n\t\t
\n\t\t\t\n\n

Our People<\/p>\n\n\n

Leadership Team<\/h2>\n\n
\n\t\n
\n\n\t\t\t
\n\t\t\t\"George\t\t<\/div>\n\t\n\t
\n\n\t\t\t\t\t

\n\t\t\t\tGeorge Quinoy\t\t\t<\/h3>\n\t\t\n\t\t\t\t\tPresident and CEO<\/span>\n\t\t\n\t\t
\n\t\t\t\n\n

Mr. Quinoy is a seasoned C-suite executive with a proven track record of building and scaling commercial enterprises in the medical device and vascular space.<\/p>\n\n\n\t\t<\/div>\n\n\t\t\t\t\t

\n\t\t\t\t

Throughout his career, George has played a pivotal role in driving rapid and sustained expansion for renowned companies, including AVE, Medtronic, ACS\/Guidant, Volcano Corp., and most recently, Provisio Medical.<\/p>\n

He has demonstrated expertise in commercialization, strategic planning, forecasting, and product launches, building world-class sales organizations that lead to successful acquisitions by industry leaders. His leadership at Volcano Corp. helped grow the company from startup to over $400 million in annual sales, culminating in the company\u2019s acquisition by Royal Philips in 2015.<\/p>\n

George holds a Bachelor of Science degree in Public Relations from the University of Florida and continues to be a key influence in vascular innovation and commercialization.<\/p>\n<\/div>\n\t\t\t<\/div>\n\n\t\t\t